查看购物车
  • Traditional Chinese
  • English
  • Japanese
基因融合检测市场 - 全球及区域分析：按类别、技术、适应症、最终用户及区域 - 分析与预测（2025-2035）
市场调查报告书
商品编码
1714079

基因融合检测市场 - 全球及区域分析：按类别、技术、适应症、最终用户及区域 - 分析与预测（2025-2035）

Gene Fusion Testing Market - A Global and Regional Analysis: Focus on Category, Technology, Indication, End User, and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 130 Pages | 商品交期: 1-5个工作天内

价格

全球基因融合检测市场是分子诊断和精准医疗的关键组成部分，专注于识别导致各种疾病（尤其是癌症）发展的基因变异，特别是基因融合。

这些测试检测出可能导致蛋白质功能失调并推动癌症进展的基因重排。随着对先进诊断技术的需求不断增加，全球基因融合检测市场正成为精准医疗不可或缺的一部分，从而能够根据每位患者独特的基因特征制定个人化治疗方案。该市场透过基于基因观察实现更有针对性和更有效的治疗，在改变癌症治疗方面发挥关键作用。

在全球基因融合检测市场中，次世代定序（NGS）、萤光原位杂合反应（FISH）和聚合酵素链锁反应（PCR）等多种技术用于检测各种癌症的基因融合。随着技术的不断进步，全球基因融合检测市场预计将呈指数级增长，为早期诊断、精准治疗选择和改善患者预后提供新的机会。个人化医疗的需求不断增长，进一步推动了全球基因融合检测市场的发展，确保根据患者的基因组成量身定制治疗，提高治疗效果，并最大限度地减少副作用。

全球基因融合检测市场正在经历显着成长，这得益于与基因融合突变相关的癌症盛行率的不断上升。这种扩展是由对早期检测、更好地选择标靶治疗和个人化医疗的日益增长的需求所推动的。此外，基因融合测试在临床实践中的应用日益广泛，进一步加速了癌症治疗中对这些诊断测试的需求。随着全球基因融合检测市场的不断发展，基因融合检测在为癌症患者提供更精准、个人化的治疗方案、改善患者整体治疗效果方面发挥关键作用。

基因融合测试是一种诊断程序，使用分子分析来检测和测试被称为基因融合的遗传异常。当位于不同染色体区域的两个不同基因异常结合形成混合基因时，就会发生基因融合。这种融合会导致异常蛋白质的产生或基因表现的改变，从而导致各种疾病的发展，包括某些癌症。癌症进展受到多种基因改变的影响，包括突变、缺失、扩增和重排，其中基因融合是重要因素。厦门诊断有限公司、Biocartis、Biocare Medical, LLC、丹纳赫集团和 F. Hoffmann-La Roche Ltd. 等业界领先公司的参与预计将推动全球基因融合检测市场的进一步成长。

此外，人工智慧预测模型可以识别可能需要额外诊断测试的患者，从而最大限度地减少耗时且昂贵的实验室检测需求。这些模型还可以发现先前未被发现的基因融合事件，提高对癌症基因组图谱的了解，并有助于全球基因融合检测市场开发标靶治疗方法。

按类别划分，研究领域预计将在 2024 年引领全球基因融合检测市场。套件、检测试剂和配件的采用率不断提高，为该领域的成长和主导地位做出了重大贡献。这些仅用于研究的检测试剂套件主要设计用于研究环境而非诊断应用，对于研究基因融合及其与各种疾病（尤其是癌症）的关係的科学家和研究人员来说至关重要。随着对这些工具的需求不断增长，研究领域预计将在全球基因融合测试市场中保持主导地位。

从技术角度来看，NGS（次世代定序）领域预计将在 2024 年主导全球基因融合检测市场。 NGS 是一种新兴的变革性技术，可提供 DNA 和 RNA 序列的高通量和准确分析，并在基因融合检测中发挥关键作用。在基因融合检测中，NGS有助于全面检测基因重排，以便能够以极高的准确度精确识别不同基因之间的融合事件。随着NGS的不断发展，预计它将在全球基因融合检测市场中保持主导。

根据适应症，预计固态肿瘤领域将在 2024 年引领全球基因融合检测市场。在肿瘤学中，固态肿瘤的基因融合检测是分子诊断的重要组成部分，专注于识别由癌细胞中的染色体重排和易位引起的特定基因融合。这些基因融合导致异常融合蛋白的产生，并在固体癌的进展和发展中发挥重要作用。随着对精准癌症诊断的需求不断增加，固体癌领域预计将在全球基因融合检测市场中保持主导地位。

根据最终用户，预计製药和生物技术公司将在 2024 年占据全球基因融合检测市场的最大份额。这些公司在市场中发挥关键作用，利用他们的专业知识和资源推动这个快速发展的领域的创新和进步。製药和生物技术公司深刻认识到基因融合检测的巨大潜力，主导主要企业癌症诊断和治疗策略的革新，确保全球基因融合检测市场的持续成长和发展。

欧洲市场以德国为主，预计英国的成长率最高。英国正采取合作方式开发基因融合检测技术。此外，该国以其强大的学术研究机构而闻名，这些机构在推动基因检测技术和推动全球基因融合检测市场的创新方面发挥关键作用。

基因融合检测市场是医疗保健产业的一个重要领域，致力于开发、生产和商业化用于检测和分析基因融合的测试和技术。此测试可识别异常融合事件，即两种不同的基因融合在一起形成功能改变的融合蛋白，这些事件通常与各种疾病有关，尤其是癌症。本研究探讨了推动基因融合检测进步的几种核心技术，包括聚合酵素链锁反应(PCR)、次世代次世代定序(NGS)、免疫组织化学 (IHC) 和萤光原位杂合技术(FISH)。全球基因融合检测市场的扩张受到创新技术的不断引入以及政府和私营部门不断增加的投资和资金筹措的推动。

工作流程/创新策略：基因融合检测市场依适应症分为固体癌和骨髓恶性肿瘤。此外，本研究对基因融合检测在固体癌中的多种应用进行了彻底的分析，让读者全面了解其在识别与这些特定癌症类型相关的基因融合中的作用。

成长/行销策略：基因融合测试是一种分子诊断技术，用于识别和分析癌细胞中的特定基因变化。当两个不同的基因（通常位于不同的染色体上）异常融合在一起，形成混合基因，产生具有改变功能的独特蛋白质时，就会发生这种情况。

竞争策略：该研究对全球基因融合测试市场的主要企业（包括製造商）进行了全面的分析和分析。此外，它还对这些参与企业进行了深入的竞争基准化分析，让读者清楚地了解他们之间的比较情况，并全面了解市场格局。

本报告研究了全球基因融合测试市场，并概述了市场趋势、类别、技术、适应症、最终用户和地区，以及参与市场的公司概况。

目录

执行摘要

第一章 产品定义

第二章 市场范围

第三章调查方法

第四章 市场概述

  • 基因融合检测简介
    • 基因融合检测的各种技术
    • 基因融合检测的优点与局限性
    • 当前市场规模和未来成长潜力（百万美元，2023-2035 年）
    • 人工智慧 (AI) 和机器学习 (ML) 在基因融合测试中的作用
    • 兑换状态
  • 相关利益者调查回复
    • 对基因融合检测的认识
    • 了解以下公司的 NGS 服务：
    • 基因融合检测的介绍与障碍

第五章 产业展望

  • 监管状况
    • 美国法律要求与框架
    • 欧洲法律要求和框架
    • 亚太地区的法律要求与框架

6. 全球基因融合检测市场：市场动态

  • 影响分析
  • 市场驱动因素
  • 市场限制
  • 市场机会

第七章全球基因融合测试市场：竞争考察

  • 概述
  • 关键策略和发展
    • 产品核准和发布
    • 伙伴关係和合作
    • 合併与收购
    • 其他进展
  • 市场占有率分析
    • 按公司
  • 成长份额分析

8. 全球基因融合检测市场（按类别划分）（百万美元），2023 年至 2035 年

  • 概述
  • 研究
  • 诊断

9. 全球基因融合检测（依技术划分）（百万美元），2023 年至 2035 年

  • 概述
  • 次世代定序（NGS）
  • 萤光原位杂合技术（FISH）
  • 聚合酵素链锁反应（PCR）
  • 免疫组织化学（IHC）

10. 全球基因融合检测市场（依适应症划分）（百万美元），2023 年至 2035 年

  • 概述
  • 固态肿瘤
    • 肺癌
    • 乳癌
    • 大肠直肠癌
    • 甲状腺癌
    • 其他的
  • 造血系统恶性肿瘤

11. 全球基因融合检测市场，依最终用户划分（百万美元），2023 年至 2035 年

  • 概述
  • 製药和生物技术公司
  • 医院和诊断实验室
  • 研究与学术中心

12. 全球基因融合检测市场（按地区划分）（百万美元），2023 年至 2035 年

  • 概述
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 其他地区

第十三章竞争格局与公司概况

  • 竞争格局
  • Amoy Diagnostics Co., Ltd.
  • Arima Genomics
  • Biocartis
  • Biocare Medical, LLC
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Guardant Health, Inc
  • Illumina, Inc.
  • Invitae Corporation
  • Myriad Genetics, Inc.
  • NeoGenomics, Inc.
  • OncoDNA
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.
Product Code: BHP1416SB

Global Gene Fusion Testing Market Industry Overview

The global gene fusion testing market is a critical component of molecular diagnostics and precision medicine, focused on identifying genetic alterations, specifically gene fusions, that contribute to the development of various diseases, particularly cancer. These tests detect gene rearrangements that may lead to abnormal protein functions, driving cancer progression. As the demand for advanced diagnostic technologies grows, the global gene fusion testing market has become essential in precision medicine, enabling the development of personalized treatments tailored to the unique genetic profiles of individual patients. This market plays a vital role in transforming cancer care, allowing for more targeted and effective therapies based on genetic findings.

In the global gene fusion testing market, several technologies such as next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), and polymerase chain reaction (PCR) are used to detect gene fusions in various cancers. As advancements continue, the global gene fusion testing market is expected to grow exponentially, offering new opportunities for early diagnosis, precise treatment selection, and improved patient outcomes. The rising demand for personalized medicine further propels the global gene fusion testing market, ensuring that patients receive treatments tailored to their genetic makeup, enhancing the effectiveness of therapies and minimizing side effects.

Market Lifecycle Stage

The global gene fusion testing market is experiencing significant growth, fueled by the rising prevalence of cancer associated with gene fusion mutations. The increasing demand for early detection, precise selection of targeted therapies, and personalized medicine is driving this expansion. Additionally, the growing adoption of gene fusion testing in clinical practice is further accelerating the need for these diagnostic tests in cancer care. As the global gene fusion testing market continues to evolve, it plays a crucial role in enabling more accurate and individualized treatment options for cancer patients, improving overall patient outcomes.

Impact

Gene fusion testing is a diagnostic method that employs molecular analysis to detect and examine genetic abnormalities known as gene fusions. These occur when two distinct genes from different chromosomal regions become abnormally joined, creating a hybrid gene. This fusion can result in the production of abnormal proteins or changes in gene expression, potentially contributing to the development of various diseases, including certain cancers. Cancer progression is influenced by multiple genetic alterations, such as mutations, deletions, amplifications, and rearrangements, with gene fusions being a key factor. The involvement of leading industry players, including Amoy Diagnostics Co., Ltd., Biocartis, Biocare Medical, LLC, Danaher Corporation, and F. Hoffmann-La Roche Ltd., is expected to drive further growth in the global gene fusion testing market.

In addition, AI-powered prediction models offer the potential to minimize the need for time-consuming and expensive laboratory assays by identifying patients who may require additional diagnostic testing. These models could also uncover previously undetected gene fusion events, improving the understanding of the genomic landscape of cancers and supporting the development of targeted therapeutic approaches in the global gene fusion testing market.

Market Segmentation:

Segmentation 1: by Category

  • Research
  • Diagnostic

Research to Continue its Dominance in the by Category Segment

In terms of category type, the research segment is anticipated to lead the global gene fusion testing market in FY2024. The increasing adoption of kits, assays, and accessories has greatly contributed to the growth and prominence of this segment. These research-specific assays and kits, primarily designed for use in research settings rather than diagnostic applications, are vital for scientists and researchers studying gene fusions and their involvement in various diseases, especially cancer. As demand for these tools continues to rise, the research segment is set to maintain its dominant position in the global gene fusion testing market.

Segmentation 2: by Technology

  • NGS
  • FISH
  • PCR
  • IHC

NGS to Continue its Dominance in the Technology Segment

Based on technology, the NGS (Next-Generation Sequencing) segment is projected to dominate the global gene fusion testing market in FY2024. NGS is an advanced and transformative technology that plays a pivotal role in gene fusion testing, providing high-throughput and accurate analysis of DNA and RNA sequences. In the context of gene fusion testing, NGS facilitates a comprehensive examination of genetic rearrangements, enabling the precise identification of fusion events between different genes with exceptional accuracy. As NGS continues to evolve, it is set to maintain its leading position in the global gene fusion testing market.

Segmentation 3: by Indication

  • Solid Tumors
  • Hematological Malignancies

Solid Tumors to Continue its Dominance in the Indication Segment

Based on indication, the solid tumors segment is anticipated to lead the global gene fusion testing market in FY2024. In oncology, gene fusion testing for solid tumors is crucial in molecular diagnostics, focusing on identifying specific gene fusions caused by chromosomal rearrangements or translocations within tumor cells. These gene fusions can result in the production of abnormal fusion proteins, which play a significant role in the progression and development of solid tumors. As the demand for precise cancer diagnostics increases, the solid tumors segment is expected to maintain its dominance in the global gene fusion testing market.

Segmentation 4: by End User

  • Pharmaceutical and Biotechnology Companies
  • Hospitals and Diagnostic Laboratories
  • Academic and Research Centers

Pharmaceutical and Biotechnology Companies to Continue its Dominance in the End User Segment

Based on end user, the pharmaceutical and biotechnology companies segment is expected to hold the largest share of the global gene fusion testing market in FY2024. These companies play a crucial role in the market, utilizing their expertise and resources to drive innovation and promote advancements in this rapidly evolving field. With a keen understanding of the significant potential of gene fusion testing, pharmaceutical and biotechnology companies are leading efforts to revolutionize cancer diagnostics and treatment strategies, ensuring continued growth and development in the global gene fusion testing market.

Segmentation 5: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Rest-of-the-World

U.K. to Continue its Dominance as the Leading Country in Europe Region

Germany is the dominant market in Europe, with the U.K. projected to experience the highest growth rate. The U.K. has adopted a supportive approach towards the development of gene fusion testing technologies. Furthermore, the country is known for its robust academic and research institutions, which play a critical role in advancing genetic testing technologies and driving innovation in the global gene fusion testing market.

Demand - Drivers and Limitations

Market Demand Drivers:

  • Growing Prevalence of Cancer Driven by Gene Fusion Mutations
  • Expanding Use of Gene Fusion Testing in Targeted Therapy Development
  • Global Increase in Research Funding Focused on Cancer Screening and Prevention

Market Restraints:

  • Challenges Due to the Complexity of the Testing Process
  • Issues with Standardization and Barriers in Reimbursement Policies

Market Opportunities:

  • Growing Demand for Gene Fusion Testing in Clinical Research
  • Utilizing Artificial Intelligence to Predict Gene Fusion Status Across Various Cancer Types

The gene fusion testing market is a crucial segment within the healthcare industry, dedicated to the development, production, and commercialization of tests and technologies aimed at detecting and analyzing gene fusions. This testing identifies abnormal fusion events where two distinct genes merge to form fusion proteins with modified functions, often linked to various diseases, particularly cancer. This study explores several core technologies that have driven advancements in gene fusion testing, including polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), and fluorescence in-situ hybridization (FISH). The expansion of the global gene fusion testing market is fueled by the ongoing introduction of innovative technologies and increasing investments and funding from both government and private sectors.

How can this report add value to an organization?

Workflow/Innovation Strategy: The gene fusion testing market, segmented by indication, comprises solid tumors and hematological malignancies. Furthermore, the study provides a thorough analysis of the diverse applications of gene fusion testing in solid tumors, offering readers a comprehensive understanding of its role in identifying gene fusions linked to these specific cancer types.

Growth/Marketing Strategy: Gene fusion testing is a molecular diagnostic technique employed to identify and analyze specific genetic alterations in cancer cells. It occurs when two distinct genes, typically located on different chromosomes, fuse abnormally, creating a hybrid gene that generates a unique protein with modified functions.

Competitive Strategy: Key players in the global gene fusion testing market have been extensively analyzed and profiled in this study, including manufacturers. Furthermore, a detailed competitive benchmarking of these players has been performed to give readers a clear insight into how companies measure up against each other, presenting a comprehensive view of the market landscape.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • Detailed secondary research to ensure maximum coverage of manufacturers/suppliers operational in a country.
  • Exact revenue information, up to a certain extent, will be extracted for each company from secondary sources and databases. Revenues specific to product/service/technology will then be estimated for each market player based on fact-based proxy indicators as well as primary inputs.
  • The currency conversion rate has been taken from the historical exchange rate of Oanda and/or other relevant websites.
  • Any economic downturn in the future has not been taken into consideration for the market estimation and forecast.
  • The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year.
  • The term "product" in this document may refer to "service" or "technology" as and where relevant.
  • The term "manufacturers/suppliers" may refer to "service providers" or "technology providers" as and where relevant.

Primary Research

The key data points taken from the primary sources include:

  • Validation and triangulation of all the numbers and graphs
  • Validation of the report's segmentation and key qualitative findings
  • Understanding of the numbers of the various markets for market type
  • Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Food and Drug Administration (FDA), European Medical Agency (EMA), National Medical Product Administration (NMPA), Ministry of Health, Labor, and Welfare (MHLW), Pharmaceutical and Medical Devices Association (PMDA), Frontiers, and World Intellectual Property Organization (WIPO)
  • Annual reports, SEC filings, and investor presentations of the leading market players
  • Company websites and detailed study of their portfolio
  • Gold standard magazines, journals, whitepapers, press releases, and news articles
  • Databases

The key data points taken from the secondary sources include:

  • Segmentations, split-ups, and percentage shares
  • Data for market value
  • Key industry trends of the top players in the market
  • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.

Some of the prominent companies in this market are:

  • Amoy Diagnostics Co., Ltd.
  • Biocartis
  • Biocare Medical, LLC
  • F. Hoffmann-La Roche Ltd
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.

Companies that are not a part of the aforementioned pool have been well represented across different sections of the report (wherever applicable).

Table of Contents

Executive Summary

1. Product definition

  • 1.1 Inclusion and Exclusion Criteria

2. Market Scope

  • 2.1 Scope of the Study
  • 2.2 Key Questions Answered in the Report

3. Research Methodology

4. Market Overview

  • 4.1 Introduction to Gene Fusion Testing
    • 4.1.1 Different Technologies for Gene Fusion Testing
    • 4.1.2 Advantages and Limitations of Gene Fusion Testing
    • 4.1.3 Current Market Size and Future Growth Potential, $Million, 2023-2035
    • 4.1.4 Role of Artificial Intelligence (AI) and Machine Learning (ML) in Gene Fusion Testing
    • 4.1.5 Reimbursement Landscape
  • 4.2 Stakeholder's Survey Response
    • 4.2.1 Awareness of Gene Fusion Testing
    • 4.2.2 Familiarity with the NGS Offerings of the Following Companies
    • 4.2.3 Adoption and Barriers for Gene Fusion Testing

5. Industry Outlook

  • 5.1 Regulatory Landscape
    • 5.1.1 Legal Requirements and Frameworks in the U.S.
    • 5.1.2 Legal Requirements and Frameworks in Europe
    • 5.1.3 Legal Requirements and Frameworks in Asia-Pacific
      • 5.1.3.1 Legal Requirements and Framework in China
      • 5.1.3.2 Legal Requirements and Framework in Japan

6. Global Gene Fusion Testing Market: Market Dynamics

  • 6.1 Impact Analysis
  • 6.2 Market Drivers
  • 6.3 Market Restraints
  • 6.4 Market Opportunities

7. Global Gene Fusion Testing Market: Competitive Insights

  • 7.1 Overview
  • 7.2 Key Strategies and Developments
    • 7.2.1 Product Approvals and Launches
    • 7.2.2 Partnerships and Collaborations
    • 7.2.3 Mergers and Acquisitions
    • 7.2.4 Other Developments
  • 7.3 Market Share Analysis
    • 7.3.1 By Company
  • 7.4 Growth-Share Analysis

8. Global Gene Fusion Testing Market (by Category), ($Million), 2023-2035

  • 8.1 Overview
  • 8.2 Research
  • 8.3 Diagnostic

9. Global Gene Fusion Testing (by Technology), ($Million), 2023-2035

  • 9.1 Overview
  • 9.2 Next-Generation Sequencing (NGS)
  • 9.3 Fluorescence In-Situ Hybridization (FISH)
  • 9.4 Polymerase Chain Reaction (PCR)
  • 9.5 Immunohistochemistry (IHC)

10. Global Gene Fusion Testing Market (by Indication), ($Million), 2023-2035

  • 10.1 Overview
  • 10.2 Solid Tumors
    • 10.2.1 Lung Cancer
    • 10.2.2 Breast Cancer
    • 10.2.3 Colorectal Cancer
    • 10.2.4 Thyroid Cancer
    • 10.2.5 Others
  • 10.3 Hematological Malignancies

11. Global Gene Fusion Testing Market (by End User), ($Million), 2023-2035

  • 11.1 Overview
  • 11.2 Pharmaceutical and Biotechnology Companies
  • 11.3 Hospitals and Diagnostic Laboratories
  • 11.4 Research and Academic Centers

12. Global Gene Fusion Testing Market (by Region), ($Million), 2023-2035

  • 12.1 Overview
  • 12.2 North America
    • 12.2.1 North America Gene Fusion Testing Market, by Indication
    • 12.2.2 North America Gene Fusion Testing Market (by Country)
      • 12.2.2.1 U.S.
        • 12.2.2.1.1 U.S. Gene Fusion Testing Market (by Indication)
      • 12.2.2.2 Canada
        • 12.2.2.2.1 Canada Gene Fusion Testing Market (by Indication)
  • 12.3 Europe
    • 12.3.1 Europe Gene Fusion Testing Market, by Indication
    • 12.3.2 Europe Gene Fusion Testing Market (by Country)
      • 12.3.2.1 Germany
        • 12.3.2.1.1 Germany Gene Fusion Testing Market (by Indication)
      • 12.3.2.2 France
        • 12.3.2.2.1 France Gene Fusion Testing Market (by Indication)
      • 12.3.2.3 U.K.
        • 12.3.2.3.1 U.K. Gene Fusion Testing Market (by Indication)
      • 12.3.2.4 Italy
        • 12.3.2.4.1 Italy Gene Fusion Testing Market (by Indication)
      • 12.3.2.5 Spain
        • 12.3.2.5.1 Spain Gene Fusion Testing Market (by Indication)
      • 12.3.2.6 Netherlands
        • 12.3.2.6.1 Netherlands Gene Fusion Testing Market (by Indication)
      • 12.3.2.7 Rest-of-the-Europe
        • 12.3.2.7.1 Rest-of-the-Europe Gene Fusion Testing Market (by Indication)
  • 12.4 Asia-Pacific
    • 12.4.1 Asia-Pacific Gene Fusion Testing Market, by Indication
    • 12.4.2 Asia-Pacific Gene Fusion Testing Market (by Country)
      • 12.4.2.1 China
        • 12.4.2.1.1 China Gene Fusion Testing Market (by Indication)
      • 12.4.2.2 Japan
        • 12.4.2.2.1 Japan Gene Fusion Testing Market (by Indication)
      • 12.4.2.3 India
        • 12.4.2.3.1 India Gene Fusion Testing Market (by Indication)
      • 12.4.2.4 Australia
        • 12.4.2.4.1 Australia Gene Fusion Testing Market (by Indication)
      • 12.4.2.5 South Korea
        • 12.4.2.5.1 South Korea Fusion Testing Market (by Indication)
      • 12.4.2.6 Rest-of-Asia-Pacific
        • 12.4.2.6.1 Rest-of-Asia-Pacific Gene Fusion Testing Market (by Indication)
  • 12.5 Latin America
    • 12.5.1 Latin America Gene Fusion Testing Market, by Indication
    • 12.5.2 Latin America Gene Fusion Testing Market (by Country)
      • 12.5.2.1 Brazil
        • 12.5.2.1.1 Brazil Gene Fusion Testing Market (by Indication)
      • 12.5.2.2 Mexico
        • 12.5.2.2.1 Mexico Gene Fusion Testing Market (by Indication)
      • 12.5.2.3 Rest-of-Latin America
        • 12.5.2.3.1 Rest-of-Latin America Gene Fusion Testing Market (by Indication)
  • 12.6 Rest-of-the-World
    • 12.6.1 Rest-of-the-World Gene Fusion Testing Market (by Indication)

13. Competitive Landscape and Company Profiles

  • 13.1 Competitive Landscape
    • 13.1.1 New Offerings
    • 13.1.2 Mergers and Acquisitions
    • 13.1.3 Partnerships, Alliances, and Business Expansion
    • 13.1.4 Funding Activities
    • 13.1.5 Regulatory Approvals
  • 13.2 Amoy Diagnostics Co., Ltd.
    • 13.2.1 Overview
    • 13.2.2 Type Portfolio
    • 13.2.3 Target Customers
    • 13.2.4 Key Professionals
    • 13.2.5 Analyst View
  • 13.3 Arima Genomics
    • 13.3.1 Overview
    • 13.3.2 Product Portfolio
    • 13.3.3 Target Customers
    • 13.3.4 Key Professionals
    • 13.3.5 Analyst View
  • 13.4 Biocartis
    • 13.4.1 Overview
    • 13.4.2 Product Portfolio
    • 13.4.3 Target Customers
    • 13.4.4 Key Professionals
    • 13.4.5 Analyst View
  • 13.5 Biocare Medical, LLC
    • 13.5.1 Overview
    • 13.5.2 Product Portfolio
    • 13.5.3 Target Customers
    • 13.5.4 Key Professionals
    • 13.5.5 Analyst View
  • 13.6 Bio-Rad Laboratories, Inc.
    • 13.6.1 Overview
    • 13.6.2 Product Portfolio
    • 13.6.3 Target Customers
    • 13.6.4 Key Professionals
    • 13.6.5 Analyst View
  • 13.7 F. Hoffmann-La Roche Ltd
    • 13.7.1 Overview
    • 13.7.2 Product Portfolio
    • 13.7.3 Target Customers
    • 13.7.4 Key Professionals
    • 13.7.5 Analyst View
  • 13.8 Guardant Health, Inc
    • 13.8.1 Overview
    • 13.8.2 Product Portfolio
    • 13.8.3 Target Customers
    • 13.8.4 Key Professionals
    • 13.8.5 Analyst View
  • 13.9 Illumina, Inc.
    • 13.9.1 Overview
    • 13.9.2 Product Portfolio
    • 13.9.3 Target Customers
    • 13.9.4 Key Professionals
    • 13.9.5 Analyst View
  • 13.10 Invitae Corporation
    • 13.10.1 Overview
    • 13.10.2 Product Portfolio
    • 13.10.3 Target Customers
    • 13.10.4 Key Professionals
    • 13.10.5 Analyst View
  • 13.11 Myriad Genetics, Inc.
    • 13.11.1 Overview
    • 13.11.2 Product Portfolio
    • 13.11.3 Target Customers
    • 13.11.4 Key Professionals
    • 13.11.5 Analyst View
  • 13.12 NeoGenomics, Inc.
    • 13.12.1 Overview
    • 13.12.2 Product Portfolio
    • 13.12.3 Target Customers
    • 13.12.4 Key Professionals
    • 13.12.5 Analyst View
  • 13.13 OncoDNA
    • 13.13.1 Overview
    • 13.13.2 Product Portfolio
    • 13.13.3 Target Customers
    • 13.13.4 Key Professionals
    • 13.13.5 Analyst View
  • 13.14 PerkinElmer, Inc.
    • 13.14.1 Overview
    • 13.14.2 Product Portfolio
    • 13.14.3 Target Customers
    • 13.14.4 Key Professionals
    • 13.14.5 Analyst View
  • 13.15 QIAGEN N.V.
    • 13.15.1 Overview
    • 13.15.2 Product Portfolio
    • 13.15.3 Target Customers
    • 13.15.4 Key Professionals
    • 13.15.5 Analyst View
  • 13.16 Thermo Fisher Scientific Inc.
    • 13.16.1 Overview
    • 13.16.2 Product Portfolio
    • 13.16.3 Target Customers
    • 13.16.4 Key Professionals
    • 13.16.5 Analyst View

List of Figures

  • Figure: Global Gene Fusion Testing Market, Dynamics Impact Analysis
  • Figure: Global Gene Fusion Testing Market Coverage
  • Figure: Global Gene Fusion Testing Market, Key Trends, Impact Analysis, 2023-2035
  • Figure: Global Gene Fusion Testing Market, Patent Analysis, January 2022-March 2025
  • Figure: Global Gene Fusion Testing Market, Competitive Landscape, January 2022-March 2025

List of Tables

  • Table: Global Gene Fusion Testing Market Dynamics, Impact Analysis
  • Table: Global Gene Fusion Testing Market (by Category), $Million, 2023-2035
  • Table: Global Gene Fusion Testing Market (by Technology), $Million, 2023-2035
  • Table: Global Gene Fusion Testing Market (by Indication), $Million, 2023-2035
  • Table: Global Gene Fusion Testing Market (by End User), $Million, 2023-2035